
Over 90% of rare diseases have no treatment...

- There are more than 6,000 known rare diseases...
- Approximately 80% of them have a genetic component... 75% affect children...
- And most rare diseases are chronic conditions, many of which progress overtime and are potentially fatal...

Understanding the rare disease framework is key to be able to offer study participants adapted solutions and as such, positively contribute to important and necessary clinical research conducted on rare diseases.

Kayentis offers an extensive experience in rare disease clinical trials, in indications such as:

- Prader-Willi Syndrome
- PIK3CA-related overgrowth spectrum
 - Auto-Immune Hepatitis (AIH)
 - Hypoparathyroidism
 - Sjögren's syndrome
 - Acute Vertigo

RARE DISEASE CASE STUDY

Kayentis offers an extensive experience in rare disease clinical trials

IN INDICATIONS SUCH AS:


- Prader-Willi Syndrome
- PIK3CA-related overgrowth spectrum
- Auto-Immune Hepatitis (AIH)
- Hypoparathyroidism
- Sjögren's syndrome
- Acute Vertigo

UP TO 38 COUNTRIES

AROUND 2,500 PATIENTS ABOUT 1,000 SITES ACROSS THE GLOBE: Europe – US – Asia – Oceania

ASSESSMENTS

- **PROs:** Appetite NRS, EQ-5D-5L SELF, Vertigo Intensity, DSS-SF, Nausea Severity, DHI, Vestibular Disorders Activities of Daily Living Scale - PROMIS Fatigue, SF 13A, SF-12, Injection-Site Reaction Questionnaire
- **Pediatric PROs:** PedsQL™ Young Adult (ages 18-25), PedsQL™ Pediatric (ages 12-18)
- **ObsROs:** EQ-5D-5L PROXY, PedsQL™ Adult, HQ-CT, CgGIS-H, CgGIC-H, Zarit Burden Interview Caregiver, DBC-P
- **eDiary:** Vestibular Disorders Activities of Daily Living Scale - eDiary for drug intake (IMP daily injection compliance/ Site injection/ Calcium and Vit D supplements intake count/ other treatment intake - Sjögren syndrome patient diary - SSSD
- **ClinROs:** PhGA / ESSDAI / CDAI




Download the case study
Contact us for more information

Key Words:

- eCOA

- ePRO
- eDiary
- rare disease
- clinical trial

[Learn more:](#)



How Kayentis Helps You Manage The Growing Complexities Of eCOA Trials

3 August 2023

We all know clinical trials are more and more complex, involving an increasing number of

[Read More »](#)

Emerging Biopharma & Biotech (EBP) 5 key success factors for your clinical trials

With so much at stake, consider partnering with an expert of eCOA and DCT

Kayentis has a unified platform with reliable services for successful electronic Clinical Outcome Assessment (eCOA) and decentralized clinical trials (DCT)

Emerging Biopharma & Biotech (EBP) – 5 key success factors for your clinical trials

26 July 2023

With so much at stake, consider partnering with an expert of eCOA and DCT! Kayentis

[Read More »](#)

PARTNERING WITH SITES IN CLINICAL TRIALS - SURVEY RESULTS



of sites are
very satisfied
or satisfied with
Clin'form solution



Found creating
a patient to be
easy & intuitive



Found creating
a patient to be fast

How is the Kayentis Clin'form solution perceived by site staff users?

15 June 2023

The survey, conducted in November 2022, involved 239 site respondents from Europe (47%), Americas (27%),

[Read More »](#)




Implementing electronic Patient Reported Outcomes (ePROs) in Arthritis Clinical Research: Importance, benefits, and management for incorporating ePROs

7 June 2023

Arthritis is a general term categorized by acute or chronic inflammation of the joints. Arthritis

[Read More »](#)



ePRO data collection: Decision-Making for the Adoption of a Bring Your Own Device Strategy

17 May 2023

Electronic devices have been systematically provided to participants to report Patient Reported Outcome (PRO) data

[Read More »](#)



Working With Patient Associations: What Is The Key To A Positive Interaction?

2 May 2023

What rare disease patients and families want is a simpler life. Discover here what makes

[Read More »](#)